Oncology · Multiple MyelomaTrial Updateclinicalmid-term

Bristol-Myers Squibb Evaluates Pomalidomide Outcomes in Relapsed/Refractory Multiple Myeloma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 6:32:55 PM

Assessment confidence: 92% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing study on pomalidomide outcomes in relapsed/refractory multiple myeloma is significant as it may redefine treatment protocols and competitive dynamics in this therapeutic area. Insights gained could influence clinical guidelines and positioning of pomalidomide against other therapies. Regulatory context from FDA (FDA AP — POMALIDOMIDE (SUPPL)) supports the near-term read. Assessment grounded in 31 ranked evidence items (31 high-relevance).

Strategic Assessment

Results could inform treatment strategies and positioning of pomalidomide in the market, influencing future clinical guidelines. The strongest clinical anchor is Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens (ClinicalTrials.gov), entity match (pomalidomide); patient population match (refractory). In Oncology · Multiple Myeloma, 8 regulatory and 7 competitive items passed relevance filtering for Bristol Myers Squibb.

Competitive Pressure

The most relevant competitive pressure comes from U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma (Bristol Myers Squibb) — entity match (bristol myers squibb); patient population match (refractory).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — POMALIDOMIDE (SUPPL) (FDA). Entity match (pomalidomide); Regulatory pathway relevance (nda). The findings may lead to updates in treatment guidelines, which could influence regulatory considerations for pomalidomide's use in clinical practice.

Key Risks

Elevated medium regulatory exposure for Bristol Myers Squibb could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Depending on the study results, there could be shifts in market share for pomalidomide, affecting revenue streams for Bristol-Myers Squibb and competitors in the multiple myeloma space.
Bristol Myers Squibb document relevant to the signal.
Upside for Bristol Myers Squibb may improve if A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Bristol Myers Squibb may improve if Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Genentech, Inc.. The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

What Would Change This Assessment

This becomes more urgent if Monitor for study results and their impact on treatment protocols and competitive landscape in multiple myeloma.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — POMALIDOMIDE (SUPPL)
FDAhigh relevance
Entity match (pomalidomide); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Regulatory pathway relevance (nda)
FDA document
View source

Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
ClinicalTrials.govhigh relevance
Entity match (pomalidomide); Patient population match (refractory)
FDA document
View source
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effect of Participating in Study of Causes of Pregnancy Loss on Mental Health Outcomes: A Target Trial Emulation Using the COPL Cohort and Danish National Registries
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb); Patient population match (refractory)
FDA document
View source
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb); Patient population match (refractory)
FDA document
View source
NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
Bristol Myers Squibbhigh relevance
Entity match (bristol myers squibb); Patient population match (refractory)
FDA document
View source
SonoCloud-9 Enhances Carboplatin Delivery in Recurrent Glioblastoma Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Bristol Myers Squibb)

Immunotherapy in pediatric bone sarcomas: Current progress and future directions.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
RBMS1 enhances PDPK1 mRNA stability to promote multiple myeloma malignancy and M2 macrophage polarization.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bristol Myers Squibb
Pomalidomide

Commercial impact

medium

Depending on the study results, there could be shifts in market share for pomalidomide, affecting revenue streams for Bristol-Myers Squibb and competitors in the multiple myeloma space.

Regulatory impact

medium

The findings may lead to updates in treatment guidelines, which could influence regulatory considerations for pomalidomide's use in clinical practice.

What to watch

Monitor for study results and their impact on treatment protocols and competitive landscape in multiple myeloma.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.